Skip to content

Multicenter Registry for Chest Wall Reconstruction Using Custom Dynamic Prostheses (PRODIPET)

Multicenter Registry for Chest Wall Reconstruction Surgery Using Custom Dynamic Prostheses PRODIPET

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07018960
Acronym
PRODIPET
Enrollment
60
Registered
2025-06-13
Start date
2024-03-01
Completion date
2025-12-31
Last updated
2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chest Wall Tumors, Malignant Bone Tumor of Chest Wall, Post-traumatic Syndrome

Keywords

Chest wall tumors, Chest wall reconstruction, Custom 3D-Printed Titanium Prostheses

Brief summary

PRODIPET Study Summary Title: Multicenter Registry for Chest Wall Reconstruction Using Custom 3D-Printed Titanium Prostheses Purpose The PRODIPET study evaluates the safety and effectiveness of personalized, dynamic titanium prostheses for reconstructing the chest wall after: Tumor resection (e.g., sarcomas, lung cancer). Severe trauma (e.g., multiple rib fractures). Traditional methods (metal plates, mesh) often lack flexibility, potentially causing pain or breathing difficulties. This study tests 3D-printed titanium implants designed to mimic natural rib movement, improving function and comfort. Study Design Type: Multicenter, ambispective (retrospective + prospective data). Duration: Prospective: 24 months (Jan 2024-Jan 2026). Follow-up: 12 months per patient (final analysis by 2027). Centers: Major Spanish hospitals (Ramón y Cajal/Madrid, La Ribera/Alzira, Cruces/Baracaldo, Insular/Las Palmas). Key Goals Assess short/mid-term outcomes (pain, breathing, complications). Compare results across patients/surgical techniques. Improve future prosthesis designs. Who Can Participate? Inclusion: Adults (18+) needing chest wall reconstruction. Signed consent for anonymized data sharing. Exclusion: Titanium allergies. Participation in conflicting studies. Patient Experience Pre-Surgery: CT scan creates a custom 3D prosthesis (made by Osteobionix® using Ti6AL4V-ELI titanium). Surgery: Surgeons implant the prosthesis, anchoring it to ribs/sternum. Follow-Up: Evaluations at discharge, 1/6/12 months (in-person or phone). Measures: Pain, lung function, imaging (X-ray/CT), complications (e.g., infection, implant failure). Privacy & Ethics Data is anonymized and stored securely (REDCap system). Complies with European General Data Protection Regulation (EU GDPR) and Spanish data protection laws. Patients may withdraw anytime. For Healthcare Providers Collaboration: Open to thoracic surgeons/researchers. Data Access: Centralized via REDCap; analyzed by the coordinating team. Publications: Multicenter results will be published first; individual centers may later share their data. Why This Matters Addresses a gap in evidence for dynamic prostheses, which may offer: Better breathing mechanics vs. rigid materials. Fewer long-term complications (e.g., breakage). Could standardize best practices for complex reconstructions. Contact Lead Coordinator: Dr. Nicolás Moreno Mata (Hospital Ramón y Cajal, Madrid). Email: nicolas.moreno.hrc@gmail.com \| Phone: +34 647 609 363. Key Takeaways: Patients/Families: Learn if custom prostheses improve recovery. Providers: Contribute to advancing surgical options. Researchers: Access multicenter data on innovative implants.

Detailed description

Here's a detailed yet accessible description of the PRODIPET study: \*\*PRODIPET Study: A Comprehensive Multicenter Investigation into 3D-Printed Titanium Chest Wall Reconstruction\*\* \*\*Background and Rationale\*\* Chest wall defects resulting from tumor resections or traumatic injuries present significant surgical challenges. Traditional reconstruction methods using rigid materials like methylmethacrylate or steel plates often compromise respiratory mechanics and patient comfort. The PRODIPET study examines an innovative solution: patient-specific, 3D-printed titanium prostheses designed to replicate natural chest wall dynamics. \*\*Study Design and Methodology\*\* This national multicenter registry combines: * Retrospective data: Cases from participating centers where titanium prostheses were previously implanted * Prospective data: New cases enrolled over a 24-month period (January 2024-January 2026) \*\*Technical Innovation\*\* The prostheses are: * Custom-designed using preoperative CT scans * Manufactured via electron beam melting of Ti6AL4V-ELI titanium powder * Engineered to provide: * Anatomical precision * Dynamic flexibility mimicking natural rib movement * Reduced imaging artifacts for better postoperative monitoring \*\*Clinical Protocol\*\* 1. Preoperative Phase: * Multidisciplinary evaluation (surgeons, radiologists, engineers) * Virtual surgical planning using 3D reconstruction * Prosthesis fabrication by Osteobionix® (2-3 week turnaround) 2. Surgical Phase: * Resection of affected chest wall segment * Implantation of custom prosthesis * Fixation to remaining ribs/sternum 3. Postoperative Follow-up: * Standardized evaluations at: * Hospital discharge * 1 month * 6 months * 12 months * Assessments include: * Pulmonary function tests * Pain scales (VAS) * CT imaging * Quality of life questionnaires \*\*Data Collection and Management\*\* * Secure REDCap database hosted by EJIE (Informatic Society of Basque Government, IT) * Comprehensive variables tracked: * Demographic data * Surgical details (operative time, blood loss) * Prosthesis characteristics (size, fixation method) * Complication rates * Functional outcomes \*\*Participant Protection\*\* * CEIm (ethical committee)-approved protocol (Hospital Ramón y Cajal Ethics Committee) * GDPR-compliant data handling * Two-tier identification system: 1. Local centers maintain identifiable information 2. Central registry uses anonymized codes * Right to withdraw without penalty \*\*Scientific Objectives\*\* Primary: * Determine prosthesis durability (12-month failure rate) * Assess restoration of pulmonary function Secondary: * Identify optimal candidates for this technique * Establish complication profiles * Compare outcomes across surgical centers * Refine prosthesis design parameters \*\*Clinical Significance\*\* This study addresses critical gaps in thoracic reconstruction by: * Providing real-world evidence for a novel technology * Establishing standardized protocols * Creating a benchmark for future innovations * Potentially improving quality of life for patients requiring extensive chest wall resection \*\*Collaborative Structure\*\* * Coordinating Committee: 4 lead thoracic surgeons * Participating Centers: Open to all Spanish hospitals meeting criteria * Industry Partner: Osteobionix® (device fabrication only, no data access) \*\*Dissemination Plan\*\* * Interim analysis at 12 months * Final results publication anticipated 2027 * Data sharing policy: * Coordinating committee controls primary dataset * Participating centers may publish local data after multicenter publication This rigorous, patient-focused investigation represents a significant advancement in thoracic surgical care, combining cutting-edge engineering with clinical expertise to improve outcomes for patients with complex chest wall defects.

Interventions

PROCEDUREChest wall reconstruction with 3D printed titan custom prothesis

Dynamic Chest Wall Reconstruction with Patient-Specific 3D-Printed Titanium Prostheses 1\. Intervention Overview A custom-designed, 3D-printed titanium prosthesis is surgically implanted to reconstruct chest wall defects following oncologic resection or traumatic injury. The prosthesis is engineered to: Restore structural integrity of the thoracic cavity Preserve physiological chest wall dynamics during respiration Provide long-term biomechanical stability

Sponsors

Hospital Universitario de la Ribera
CollaboratorUNKNOWN
Hospital de Cruces
CollaboratorOTHER
Hospital Universitario Insular de Gran Canaria. Las Palmas de GG. Spain
CollaboratorUNKNOWN
University Hospital of Girona Dr. Josep Trueta
CollaboratorNETWORK
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients must meet ALL of the following: • Age: ≥18 years Clinical Indication: * Requires chest wall reconstruction due to: * Oncologic resection (primary tumors, metastases) * Traumatic injury (flail chest, severe rib fractures) * Post-infection/post-radiation defects * Defect Characteristics: * Involves ≥2 ribs or sternum with instability * Minimum defect size: 5 cm in largest dimension * Surgical Plan: * Scheduled for reconstruction with 3D-printed custom titanium prosthesis * Consent: Willing to provide informed consent for: * Surgery * Data collection * Follow-up evaluations *

Exclusion criteria

Patients will be excluded if ANY of the following apply: * Medical Contraindications: * Active systemic infection (e.g., sepsis) * Severe cardiopulmonary disease (FEV₁ \<30% predicted) * Uncorrectable coagulopathy (INR \>1.5) * Technical Limitations: * Inadequate soft tissue coverage for prosthesis * Vertebral column involvement requiring complex fixation * Material Incompatibility: * Known hypersensitivity to titanium alloys * Study Logistics: * Participation in another conflicting clinical trial * Inability to complete follow-up (e.g., no fixed address) * Ethical Considerations: * Pregnancy (due to elective CT scan requirements) * Prisoners or cognitively impaired patients without legal guardians

Design outcomes

Primary

MeasureTime frameDescription
Primary Respiratory Outcomes: Change from Baseline in Spirometric Parameters Following 3D-Printed Titanium Chest Wall ReconstructionFrom enrollment to the end of treatment at 1 year\*Measured via spirometry according to ATS/ERS /The American Thoracic Society/European respiratory society) standards at 30 days and 1 year postoperatively\*
Change from Preoperative Baseline in Forced Vital Capacity (FVC)From enrollment to the end of treatment at 1 year\*Measured via spirometry according to ATS/ERS standards at 30 days and 1 year postoperatively\*
Change from Preoperative Baseline in FEV₁/FVC RatioFrom enrollment to the end of treatment at 1 yearCalculated from spirometry results at 30 days and 1 year postoperatively
Change from Preoperative Baseline in Peak Expiratory Flow (PEF)From enrollment to the end of treatment at 1 yearMeasured via spirometry at 30 days and 1 year postoperatively
Change from Preoperative Baseline in Forced Expiratory Flow 25-75% (FEF₂₅-₇₅%)From enrollment to the end of treatment at 1 yearMeasured via spirometry at 30 days and 1 year postoperatively

Countries

Spain

Contacts

Primary ContactNicolás Moreno Mata MD, PhD, Medicine
nicolas.moreno.hrc@gmail.com0034 647609363

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026